Kiora Pharmaceuticals: Strong Financial Position and Promising Clinical Developments Drive Buy Rating
I'm PortAI, I can summarize articles.
Analyst Michael Okunewitch of Maxim Group has maintained a Buy rating on Kiora Pharmaceuticals with a price target of $12.00, citing the company's strong financial position and promising clinical developments. Despite a $2.5 million operating loss in Q3 2025, Kiora has a healthy cash reserve of $19.4 million, expected to fund operations into late 2027. The company is advancing two Phase 2 studies and has secured significant commercial agreements, enhancing its outlook.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments